Glucocorticoid-driven mitochondrial damage stimulates Tau pathology

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• Prolonged glucocorticoid exposure causes brain damage, increasing risks for depression and Alzheimer's disease.
• Mitochondrial dysfunction and Tau pathology are key contributors to glucocorticoid neurotoxicity, but their underlying mechanisms and relationship are unclear.

Purpose of the Study:

• To investigate the molecular mechanisms linking glucocorticoid exposure to mitochondrial damage and Tau pathology.
• To identify therapeutic targets for mitigating glucocorticoid-induced neurotoxicity and related brain conditions.

Main Methods:

• Utilized cultured murine hippocampal neurons and dexamethasone-treated mice.
• Investigated the role of cyclophilin D and the mitochondrial permeability transition pore (mPTP).
• Tested the efficacy of mito-apocynin and mifepristone in cellular and in vivo models.

Main Results:

• Glucocorticoids upregulate cyclophilin D, promoting mPTP opening and mitochondrial damage.
• Inhibiting cyclophilin D or mPTP opening with mito-apocynin protected against mitochondrial dysfunction and Tau pathology.
• Mito-apocynin and mifepristone rescued Tau pathology in an Alzheimer's disease ex vivo model.

Conclusions:

• Mitochondrial permeability transition pore opening is a critical factor in glucocorticoid-induced mitochondrial dysfunction and subsequent Tau pathogenesis.
• Targeting mPTP opening, particularly with mitochondrially-targeted compounds like mito-apocynin, offers a promising therapeutic strategy for stress-induced brain damage and Alzheimer's disease.
• Mitochondria represent a key therapeutic target for neuroprotection against glucocorticoid-related damage and Tau pathology.